HK Stock Market Move | HENLIUS (02696) rose nearly 5% in early trading. The HLX22 head-to-head K drug for gastric cancer phase III clinical trial conducted by American researchers will be successfully held.

HENLIUS (02696) rose nearly 5% in early trading. As of the time of writing, it rose 4.1% to 58.4 Hong Kong dollars, with a turnover of 191.632 million Hong Kong dollars. On the news front, recently, HENLIUS successfully held the HLX22-GC-301 research offline researcher meeting in San Francisco, USA. The conference focused on the international multicenter Phase III clinical study HLX22-GC-301 of the company's investigational anti-HER2 monoclonal antibody HLX22 in combination with trastuzumab and chemotherapy for first-line treatment of HER2-positive advanced gastric cancer. It is worth noting that HENLIUS recently announced that it has received approval from the National Medical Products Administration for conducting clinical trials for injection of HLX43 in combination with HLX07 and slulimab injection for the treatment of late-stage solid tumors. HENLIUS plans to conduct a Phase II clinical study of this combination therapy in China once conditions are met.